Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada.
BACKGROUND Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with substantial improvements in lung function and quality of life in people with cystic fibrosis (pwCF). Its longer-term impact on work productivity and daily activity remains less well characterized. METHODS We analyzed data from the CAN-IMPACT-C...